International Drugmakers Plan for More Manufacturing, Testing Costs as Brexit Looms

Drug Industry Daily
Testifying before a UK House of Commons committee Tuesday, international pharmaceutical companies said they are already hedging their bets when it comes to the real-world consequences of Brexit, making preparations for new hurdles in manufacturing and duplications of batch release testing that could cost millions of pounds per year.

To View This Article:


Subscribe To Drug Industry Daily